Profit before payment of interest, taxes and amortization: Guardant Health Inc (GH)

Brandmark of Guardant Health (GH)

Optimizing data analysis through external outsourcing and cloud computing accelerates test turnaround times for Guardant Health, Inc. (GH). Changes in EBITDA_Co reflect current profit dynamics, where 0.00 represents the current level of the metric. High-tech proprietary laboratories in the US ensure business stability, while a focus on the domestic market mitigates geopolitical complexities regarding data protection in China.

Guardant Health, Inc. (GH) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for Guardant Health (GH)

- market price and analyst price targets:
Stock Price Guardant Corp|GH - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Guardant Health|GH - Real Price to Acquire Entire Company
- business book valuation details:
Net Asset Value per Share Guardant Health|GH - Company Book Value|Market Capitalization to Book Value guardanthealth.com|GH - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Coefficient Guardant Health, Inc.|GH - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Guardant Health Inc|GH - Company Aggregate Debts|Debt to Net Assets Guardant Health|GH - Company Long-Term Liabilities|Company Short-Term Debts Guardant Health|Quick Ratio guardanthealth.com
- earnings and market multiples details:
GH - Company Net Income|Expected Net Income Guardant Health, Inc.|GH - P/E Multiple|Price to Future Earnings Ratio guardanthealth.com|GH - PEG Multiple|EV/EBITDA Multiple Guardant Health|GH - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Guardant Health|GH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months guardanthealth.com|GH - Net earnings per share growth this year|Expected earnings per share trend next year Guardant Health, Inc.
Summary company analytics:GH, Guardant Corp
Signature product of Guardant360

Guardant Health, Inc. (GH) dominance in the liquid biopsy segment and the patent protection of its algorithms translate directly into a stable operating cash flow. This metric aggregates the daily inflow of actual funds from core operations, allowing investors to assess the efficiency of technology monetization and the resilience of a business model where smoothed dynamics confirm the asset's maturity but limit the potential for explosive capital growth.

Competitor analysis for Guardant Health, Inc.

Operating profit EBITDA Caris Corp CAI|VCYT - Profit before payment of interest, taxes and amortization|CELC: Profit before payment of interest, taxes and amortization|GRAL (GRAIL) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Myriad Genetics Inc (MYGN)|Profit before payment of interest, taxes and amortization Castle Biosciences Corp|Burning Rock Biotech Ltd (BNR) - Operating income before deduction of amortization|Operating profit EBITDA VNRX|Operating income before deduction of amortization biodesix.com|Profit before payment of interest, taxes and amortization Precipio PRPO|Operating income before deduction of amortization Check-Cap Ltd (CHEK)|Mainz Biomed - Operating profit EBITDA|Operating profit before depreciation charges OncoCyte Inc (OCX)